Idiopathic Orbital Inflammation
Conditions
Interventions
Ttreament Group:TCZ 8 mg/kg every 4 weeks,for 2-6 cycles
Sponsors
Air Force Military Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-70 years old, regardless of sex. 2. In patients with Idiopathic Orbital Inflammation who was Glucocorticoid-Refractory 3. Agree to join the group and sign a written informed consent form. 4. Those who have good compliance and agree to take drugs and accept evaluation in accordance with the requirements of the research program.
Exclusion criteria
Exclusion criteria: 1. Complicated with other orbital diseases(TAO ,IgG4). 2. With orbital Inflammation or tuberculosis or positive history of hepatitis B or C liver disease; other systemic inflammatory/ autoimmune conditions. 3. Patients with hematological diseases who are using hormones or similar experimental drugs. 4. Patients who have participated in clinical trials of other drugs or at the same time within 3 months before treatment. 5. Women during pregnancy, lactation, or women of childbearing age who are willing to become pregnant. 6. Allergic constitution or allergic to topirazumab. 7. Alcoholism, drug addicts or other uncontrollable neuropsychiatric disorders are not suitable for drug testing. 8. The researchers believe that it is not appropriate for patients to participate in other conditions of this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ocular movement,; | — |
Secondary
| Measure | Time frame |
|---|---|
| orbital pain;IL-6; | — |
Countries
China
Contacts
Public ContactYang Jun Li
Outcome results
None listed